Technology · 1 sources covering this

Longevity Startup Doses First Human in Bid to Reverse Age-Related Sight Loss

The FDA recently approved the cellular rejuvenation therapy ER-100 for human clinical trials. While vision is the first target, it could have applications for a variety of age-related disease.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

1 L · 0 C · 0 R

How 1 sources are covering this

WIREDLean L·2h ago
Longevity Startup Doses First Human in Bid to Reverse Age-Related Sight Loss
The FDA recently approved the cellular rejuvenation therapy ER-100 for human clinical trials. While vision is the first target, it could have applications for a variety of age-related disease.
Read at WIRED →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/a6de2ab52e06f5a8ec11c116a1a4466b23e7178f"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="Longevity Startup Doses First Human in Bid to Reverse Age-Related Sight Loss"></iframe>

Longevity Startup Doses First Human in Bid to Reverse Age-Related Sight Loss

How 1 sources are covering this

Longevity Startup Doses First Human in Bid to Reverse Age-Related Sight Loss

More from Technology

OpenAI Confidentially Files for IPO as Tech Rivals Compete for Cash

New HD-2D Final Fantasy announced for consoles and PC

US military claims first drone boat rescue of downed helicopter crew

Asia’s Largest Outsourcer to Slow Hiring as AI Reshapes Industry

Reader

Trust & legal

Across the network